Advarra eReg vs. Clinion ePRO
Advarra eReg vs. Clinion ePRO
| Product | Rating | Most Used By | Product Summary | Starting Price |
|---|---|---|---|---|
Advarra eReg | N/A | Advarra (formerly Forte) offers eReg, an eregulatory management system for clinical trials, designed to help users save time, improve workflows, and enhance regulatory compliance across organizations with a system designed for academic institutions managing a large volume of protocols. | N/A | |
Clinion ePRO | N/A | Clinion ePRO is an electronic patient-reported outcomes platform designed to capture patient data directly from participants through mobile and web-based applications. The platform supports real-time collection of patient-reported outcomes, diaries, questionnaires, and other study assessments while helping sponsors and CROs improve data quality, patient engagement, and study oversight. Clinion ePRO can be deployed as a standalone solution or integrated with Clinion EDC to support unified… | N/A |
| Advarra eReg | Clinion ePRO | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Editions & Modules | No answers on this topic | No answers on this topic | ||||||||||||||
| Offerings |
| |||||||||||||||
| Entry-level Setup Fee | No setup fee | No setup fee | ||||||||||||||
| Additional Details | — | — | ||||||||||||||
| More Pricing Information | ||||||||||||||||
| Advarra eReg | Clinion ePRO | |
|---|---|---|
| Small Businesses | No answers on this topic | RXNT Score 7.9 out of 10 |
| Medium-sized Companies | No answers on this topic | ![]() AdvancedMD Score 7.8 out of 10 |
| Enterprises | No answers on this topic | No answers on this topic |
| All Alternatives | View all alternatives | View all alternatives |
| Advarra eReg | Clinion ePRO | |
|---|---|---|
| Likelihood to Recommend | - (0 ratings) | 10.0 (0 ratings) |
| Advarra eReg | Clinion ePRO | |
|---|---|---|
| Pros | No answers on this topic |
|
| Return on Investment | No answers on this topic |
|
| ScreenShots | Clinion ePRO Screenshots |


